Your Diabetes Medication May Also Be Protecting Your Brain

The drug sitting in millions of medicine cabinets as a first-line treatment for type 2 diabetes may also be quietly protecting the brain. That’s not the premise of a new pharmaceutical campaign – it’s the implication of a fast-growing body of research that has assembled, across dozens of studies and hundreds of thousands of patients, a surprisingly consistent signal: certain diabetes medications are associated with meaningfully lower rates of dementia.

The diabetes medicine dementia risk connection has sharpened dramatically in 2025 and 2026, as researchers moved beyond broad associations and began identifying which drugs, at what stage, appear to offer the most protection. The findings matter beyond those already living with diabetes. They’re illuminating the biological mechanisms that link blood sugar dysregulation to brain deterioration – and pointing toward interventions that might, one day, be prescribed with cognition in mind.

To understand why scientists are paying such close attention, it helps to grasp just how dangerous diabetes already is for the brain – and how large the at-risk population actually is.

How Diabetes Damages the Brain

A study published in Neurology in March 2026, led by researchers at Boston University School of Public Health, found that people with type 1 diabetes were nearly three times more likely to develop dementia than people without diabetes, while those with type 2 diabetes were twice as likely. These findings held irrespective of gender, race, or ethnicity. The researchers evaluated associations using linked electronic health records and survey data from the All of Us cohort, a convenience sample of US adults.

For those with type 2 diabetes who require insulin, the risk climbs even further. A 2026 analysis found that dementia onset was 2.1 times as great among those with type 2 diabetes taking insulin compared to people without diabetes, suggesting that disease severity – and the metabolic stress that comes with it – plays a direct role in cognitive outcomes.

Type 1 diabetes accounts for about 5% of all diabetes cases, yet its association with dementia carries particular weight. Advances in medical care are helping people with type 1 diabetes live longer, making the long-term effects on brain health increasingly important to understand. As lead author Jennifer Weuve, MPH, ScD, a professor of epidemiology at Boston University School of Public Health, put it: “As advances in medical care have extended the lives of people with type 1 diabetes, it’s becoming increasingly important to understand the relation of type 1 diabetes to the risk of dementia.”

The biological explanation for these risks isn’t simple, but one key thread runs through much of the research: insulin resistance. A 2021 paper published in Frontiers in Neuroscience found that insulin resistance increases neuroinflammation, which promotes both amyloid-beta protein deposition and aberrant tau phosphorylation – the two hallmarks of Alzheimer’s disease. In short, a brain that can’t use insulin properly may be a brain that builds up the proteins associated with cognitive decline.

The scale of the problem gives added urgency to the treatment question. Globally, the numbers are staggering – and researchers now believe the class of drugs used to treat diabetes and obesity may have protective effects for the brain as well. An estimated 7.4 million Americans aged 65 and older are living with Alzheimer’s disease in 2026, according to the Alzheimer’s Association.

The GLP-1 Signal

The most attention-grabbing findings have centered on GLP-1 receptor agonists – a class of medications that includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro). These drugs work by mimicking a natural gut hormone to help control blood sugar and, in higher doses, support significant weight loss. The brain connection emerged as researchers began tracking what else happened to patients taking them.

A large analysis pooled data from 26 different clinical trials involving more than 160,000 men and women with type 2 diabetes. While most glucose-lowering therapies were not significantly associated with a reduction in dementia risk, GLP-1 drugs were linked to a 45 percent reduction in the risk of Alzheimer’s disease and other forms of dementia.

That headline figure has been reinforced by several real-world analyses. A 2024 cohort study of over one million patients with type 2 diabetes, published in Alzheimer’s & Dementia, found that semaglutide was associated with 40% to 70% reduced risks of first-time Alzheimer’s diagnosis compared to other antidiabetic medications, including other GLP-1 receptor agonists. The largest reduction was seen when semaglutide was compared with insulin. A 2025 cohort study of about 200,000 people in the US Department of Veterans Affairs database with diabetes who started GLP-1 medication found that compared to other treatments, GLP-1 drugs were associated with a lower risk of neurocognitive disorders, including Alzheimer’s disease.

The mechanism behind this protection isn’t fully mapped. GLP-1 receptor agonists are hypothesized to cross the blood-brain barrier more effectively than other diabetes drug classes, and may improve cognition by reducing neuronal loss and vascular damage, as well as addressing processes linked to Alzheimer’s. In animal models, GLP-1 drugs have been shown to reduce amyloid-beta plaques, though longer trials in humans are needed to examine the effects on Alzheimer’s biomarkers like tau proteins.

A 2025 phase 2b clinical trial published in Nature Medicine evaluated liraglutide (a GLP-1 receptor agonist) in people with mild to moderate Alzheimer’s disease. The trial did not meet its primary outcome, although some secondary measures suggested possible benefits that require further investigation. The findings add to evidence that any effects of GLP-1 drugs on Alzheimer’s disease may depend on disease stage, with earlier intervention remaining an important area of research. GLP-1 drugs are currently approved for conditions such as type 2 diabetes and obesity, but not for Alzheimer’s disease prevention or treatment.

The Case for Metformin

While GLP-1 drugs have captured headlines, metformin – one of the oldest and most prescribed diabetes medications in the world – has quietly accumulated its own evidence base for brain protection.

A study published in Brain (Oxford) in April 2024, which examined the effect of metformin use in elderly patients with type 2 diabetes, found a significant reduction in the risk of dementia, with an adjusted hazard ratio of 0.34 – meaning metformin users were roughly 66% less likely to develop dementia than non-users in the study period. Notably, patients taking a full defined daily dose or more had a lower risk of dementia than those on lower doses, suggesting a dose-dependent relationship.

A 2026 study in the European Journal of Pharmacology added further weight, finding that metformin use is associated with a reduced risk of dementia and all-cause mortality in older adults with type 2 diabetes.

The biology here is also becoming clearer. Research has found that metformin activates an enzyme called AMPK, improves insulin resistance, decreases neuronal apoptosis (cell death), and reduces oxidative stress and the inflammatory response in the brain. These aren’t superficial effects – they target some of the same pathways implicated in Alzheimer’s progression. That said, the evidence isn’t uniform. Some studies found no reduction of Alzheimer’s risk or slowing of decline in people already with Alzheimer’s, and one study found a potential higher risk of Alzheimer’s among some Asian populations using metformin. Researchers are still working through why the findings differ across populations and study designs.

Definitive answers may come soon. An ongoing 18-month, double-blind, placebo-controlled trial – the Metformin in Alzheimer’s Dementia Prevention study – is investigating the protective effects of doses up to 2000 mg per day, with results expected in 2027.

SGLT2 Inhibitors and the Brain

A third class of diabetes drugs has entered the conversation with growing force: SGLT2 inhibitors (pronounced “SGLT-two”), which work by prompting the kidneys to excrete excess glucose through urine rather than reabsorbing it. Brand names include empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana).

A 2026 meta-analysis published in Endocrinology, Diabetes & Metabolism found that SGLT2 inhibitors were significantly associated with a reduced risk of incident dementia compared with DPP-4 inhibitors in patients with type 2 diabetes, including both Alzheimer’s and vascular dementia. A separate 2025 population-based cohort study found that SGLT2 inhibitor initiation was associated with a 14% lower dementia risk compared with DPP-4 inhibitor initiation, according to research published in Alzheimer’s Research & Therapy.

Observational data drawn from two large US patient databases indicate that initiating GLP-1 receptor agonists and SGLT2 inhibitors is associated with a significantly reduced risk of Alzheimer’s disease compared with starting DPP-4 inhibitors, according to a pharmacoepidemiologic study co-led by Cleveland Clinic researchers and published in Alzheimer’s & Dementia. SGLT2 inhibitors, originally developed for diabetes management, are increasingly studied for their cognitive benefits, which may include reduction of oxidative stress and neuroinflammation, decreased amyloid burden, and effects on neurotrophic factors.

Timing, Severity, and Who’s at Greatest Risk

Across this body of research, several patterns emerge that have direct practical implications. First, the severity of diabetes appears to matter significantly. Research has found that a younger age at diagnosis of type 2 diabetes was significantly associated with a higher risk of dementia, particularly among people with obesity. That means the decades-long management of blood sugar – starting from when a person is first diagnosed – may shape cognitive outcomes far down the line.

Second, the direction of effect seems stronger for prevention than treatment. Both GLP-1 drugs and metformin appear more effective at reducing the risk of dementia before it begins than at slowing cognitive decline once it has started. That shifts the question from “what can we give patients with dementia?” to “which patients should we be protecting earlier?”

Third, the underlying disease burden is accelerating. A 2026 study found that diabetes and dementia-related mortality in the US increased nearly 2.57-fold over the past two decades, from 1999 to 2023 – a trend that makes the search for effective interventions genuinely time-sensitive.

What This Means for You

The research reviewed here is largely observational, meaning it can identify associations but can’t yet prove that diabetes medications directly cause a reduction in dementia risk. Several large randomized trials are underway, and their results over the next one to two years should clarify the picture considerably. The next generation of GLP-1 drugs, expected to launch soon, may demonstrate amplified effects that could include improved neuroprotection, according to researchers currently working in this space.

For anyone living with type 2 diabetes right now, the practical takeaway is this: blood sugar control isn’t only about preventing heart disease, kidney damage, and neuropathy. It may be one of the most modifiable levers for long-term brain health. If you’re already taking metformin, a GLP-1 drug, or an SGLT2 inhibitor, the emerging evidence suggests those medications may be doing more than managing glucose. If you’re currently on an older drug class that hasn’t shown the same brain-protective signals, that’s a concrete question worth raising with your doctor: are there newer options that could offer comparable glucose control with additional neuroprotective benefits?

For those with type 1 diabetes specifically, while type 1 diabetes accounts for a small fraction of all dementia cases, for the growing number of people with type 1 diabetes who are over 65, understanding the ways in which it influences dementia risk – and how to prevent or delay it – is becoming an urgent clinical priority. Tight glucose management and consistent care remain the most evidence-based tools currently available.

The finding that a diabetes medicine dementia risk link exists – and may be modifiable through the right treatment choices – is one of the more actionable developments in dementia research in years. The brain, it turns out, is paying close attention to how well the rest of the body handles sugar.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.